Search Results

You are looking at 91 - 100 of 4,071 items for :

  • Refine by Access: All x
Clear All
Full access

Optimizing Systemic Therapy for Bladder Cancer

Sumanta K. Pal, Matthew I. Milowsky, and Elizabeth R. Plimack

Over the past decade, several advances in systemic therapy for genitourinary cancers have occurred. Since 2005, a total of 7 agents have been approved for metastatic renal cell carcinoma (RCC) based on positive phase III trials. 1 Similarly, 4

Full access

Colon Cancer

Roswell Park Cancer Institute

Colorectal cancer is the third most frequently diagnosed cancer in men and women in the United States. An estimated 112,340 new cases of colon cancer will occur in 2007 and an estimated 52,180 people will die from colon and rectal cancer in the same year. Despite these statistics, mortality from colon cancer has decreased over the past 30 years, possibly because of earlier diagnosis through screening and better treatment modalities. These guidelines begin with the clinical presentation of the patient to the primary care physician or gastroenterologist and address diagnosis, pathologic staging, surgical management, adjuvant treatment, management of recurrent and metastatic disease, and patient surveillance.

For the most recent version of the guidelines, please visit

Full access

Cervical Cancer

Stanford Comprehensive Cancer Center

An estimated 11,150 new cases of cervical cancer will be diagnosed in the United States in 2007; 3670 deaths are expected from the disease. Although cervical cancer rates are decreasing among women in the United States, it remains a major world health problem. It is the third most common cancer in women worldwide, with 78% of cases occurring in developing countries. Because persistent human papillomavirus (HPV) infection is considered the most important factor contributing to the development of cervical cancer, immunization against HPV is expected to prevent some cancer. The NCCN Clinical Practice Guidelines in Oncology discuss this and other epidemiologic risk factors, as well as treatment options.

For the most recent version of the guidelines, please visit

Full access

Understanding the Prevalence of Prediabetes and Diabetes in Patients With Cancer in Clinical Practice: A Real-World Cohort Study

Dominik J. Ose, Richard Viskochil, Andreana N. Holowatyj, Mikaela Larson, Dalton Wilson, William A. Dunson Jr, Vikrant G. Deshmukh, J. Ryan Butcher, Belinda R. Taylor, Kim Svoboda, Jennifer Leiser, Benjamin Tingey, Benjamin Haaland, David W. Wetter, Simon J. Fisher, Mia Hashibe, and Cornelia M. Ulrich

Background Cancer and diabetes are challenging health systems worldwide. In the United States, it is estimated that 5% of the population (16.9 million people) has cancer. 1 At the same time, 9.4% of the US population (30.3 million people) has

Full access

Ovarian Cancer

Duke Comprehensive Cancer Center

Ovarian neoplasms consist of several histopathologic entities, and treatment depends on the specific tumor type. Epithelial ovarian cancer comprises most malignant ovarian neoplasms; however, other pathologic subtypes (such as less common ovarian histopathologies) must be considered. These guidelines discuss epithelial ovarian cancer as well as less common ovarian histopathologies, including germ cell neoplasms, mixed müllerian tumors of the ovary, and ovarian stromal tumors.

For the most recent version of the guidelines, please visit

Full access

Prevalence of Breast Cancer Survivors Among Canadian Women

Amy A. Kirkham and Katarzyna J. Jerzak

Background Breast cancer (BC) is the most common cancer diagnosis among Canadian and American women. 1 , 2 Fortunately, since 1986, the BC mortality rate has decreased by 49% 3 ( Figure 1 ). The resultant gap between BC incidence and

Full access

Barriers to the Use of Breast Cancer Risk Reduction Therapies

Arvind Bambhroliya, Mariana Chavez-MacGregor, and Abenaa M. Brewster

NCCN: Continuing Education Accreditation Statement This activity has been designated to meet the educational needs of physicians and nurses involved in the management of patients with cancer. There is no fee for this article. No commercial

Full access

Non–Small Cell Lung Cancer, Version 1.2015

David S. Ettinger, Douglas E. Wood, Wallace Akerley, Lyudmila A. Bazhenova, Hossein Borghaei, David Ross Camidge, Richard T. Cheney, Lucian R. Chirieac, Thomas A. D’Amico, Todd L. Demmy, Thomas J. Dilling, Ramaswamy Govindan, Frederic W. Grannis Jr, Leora Horn, Thierry M. Jahan, Ritsuko Komaki, Mark G. Kris, Lee M. Krug, Rudy P. Lackner, Michael Lanuti, Rogerio Lilenbaum, Jules Lin, Billy W. Loo Jr, Renato Martins, Gregory A. Otterson, Jyoti D. Patel, Katherine M. Pisters, Karen Reckamp, Gregory J. Riely, Eric Rohren, Steven Schild, Theresa A. Shapiro, Scott J. Swanson, Kurt Tauer, Stephen C. Yang, Kristina Gregory, and Miranda Hughes

appropriate. All recommendations are category 2A unless otherwise noted. Clinical trials: NCCN believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged. Overview This

Full access

Hidden Disparities: How Language Influences Patients’ Access to Cancer Care

Debbie W. Chen, Mousumi Banerjee, Xin He, Lesley Miranda, Maya Watanabe, Christine M. Veenstra, and Megan R. Haymart

Background Despite a decline in cancer incidence and mortality rates in the United States, there continues to be an unequal burden of cancer among racial and ethnic minorities. 1 , 2 Prior work has demonstrated disparities in access to high

Full access

Risk of Cancer-Specific Death for Patients Diagnosed With Neuroendocrine Tumors: A Population-Based Analysis

Julie Hallet, Calvin Law, Simron Singh, Alyson Mahar, Sten Myrehaug, Victoria Zuk, Haoyu Zhao, Wing Chan, Angela Assal, and Natalie Coburn

Background With increasing incidence worldwide and prolonged survival in the presence of active cancer because of unique tumor biology, neuroendocrine tumors (NETs) are now more prevalent than pancreatic, esophageal, and gastric cancers